150 related articles for article (PubMed ID: 34259197)
1. Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.
Kourbanhoussen K; Joncas FH; D Wallis CJ; Hovington H; Dagenais F; Fradet Y; Guillemette C; Lacombe L; Toren P
Asian J Androl; 2022; 24(1):21-25. PubMed ID: 34259197
[TBL] [Abstract][Full Text] [Related]
2. Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2013; 90(1):45-55. PubMed ID: 23128438
[TBL] [Abstract][Full Text] [Related]
3. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
4. Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk?
Dymanus K; Howard LE; Oyekunle T; De Hoedt AM; Labadzhyan A; Polascik T; Freedland SJ; Klaassen Z
Prostate; 2022 Dec; 82(16):1558-1563. PubMed ID: 35981148
[TBL] [Abstract][Full Text] [Related]
5. Contrasts in the gonadotropin-releasing hormone dose-response relationships for luteinizing hormone, follicle-stimulating hormone and alpha-subunit release in young versus older men: appraisal with high-specificity immunoradiometric assay and deconvolution analysis.
Zwart AD; Urban RJ; Odell WD; Veldhuis JD
Eur J Endocrinol; 1996 Oct; 135(4):399-406. PubMed ID: 8921820
[TBL] [Abstract][Full Text] [Related]
6. Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?-a population-level analysis.
Dymanus K; Friedrich NA; Howard LE; Oyekunle T; De Hoedt AM; Labadzhyan A; Polascik T; Klaassen Z; Freedland SJ
Transl Androl Urol; 2023 Oct; 12(10):1540-1549. PubMed ID: 37969776
[TBL] [Abstract][Full Text] [Related]
7. Influence of radical prostatectomy on serum hormone levels.
Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
[TBL] [Abstract][Full Text] [Related]
8. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.
Murthy V; Norman AR; Barbachano Y; Parker CC; Dearnaley DP
BJU Int; 2007 Jun; 99(6):1380-2. PubMed ID: 17537213
[TBL] [Abstract][Full Text] [Related]
10. The role of FSH and LH in prostate cancer and cardiometabolic comorbidities.
Crawford ED; Schally AV
Can J Urol; 2020 Apr; 27(2):10167-10173. PubMed ID: 32333736
[TBL] [Abstract][Full Text] [Related]
11. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin subunit messenger RNA concentrations after blockade of gonadotropin-releasing hormone action: testosterone selectively increases follicle-stimulating hormone beta-subunit messenger RNA by posttranscriptional mechanisms.
Paul SJ; Ortolano GA; Haisenleder DJ; Stewart JM; Shupnik MA; Marshall JC
Mol Endocrinol; 1990 Dec; 4(12):1943-55. PubMed ID: 1707128
[TBL] [Abstract][Full Text] [Related]
13. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
[TBL] [Abstract][Full Text] [Related]
14. Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy.
Planas J; Celma A; Placer J; Maldonado X; Trilla E; Salvador C; Lorente D; Regis L; Cuadras M; Carles J; Morote J
Actas Urol Esp; 2016 Nov; 40(9):549-555. PubMed ID: 27207596
[TBL] [Abstract][Full Text] [Related]
15. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
Garnick MB; Campion M
Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
[TBL] [Abstract][Full Text] [Related]
16. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy.
Heracek J; Urban M; Sachova J; Kuncova J; Eis V; Mandys V; Hampl R; Starka L
Neuro Endocrinol Lett; 2007 Feb; 28(1):45-51. PubMed ID: 17277727
[TBL] [Abstract][Full Text] [Related]
17. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
[TBL] [Abstract][Full Text] [Related]
18. The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men.
Pitteloud N; Dwyer AA; DeCruz S; Lee H; Boepple PA; Crowley WF; Hayes FJ
J Clin Endocrinol Metab; 2008 Jul; 93(7):2686-92. PubMed ID: 18445673
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy: influence on serum and urinary androgen levels.
Olsson M; Ekström L; Schulze J; Kjellman A; Akre O; Rane A; Gustafsson O
Prostate; 2010 Feb; 70(2):200-5. PubMed ID: 19760638
[TBL] [Abstract][Full Text] [Related]
20. Sex hormone-binding globulin is an independent predictor of biochemical recurrence after radical prostatectomy.
Waldert M; Schatzl G; Swietek N; Rom M; Klatte T
J Urol; 2012 Sep; 188(3):792-7. PubMed ID: 22818139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
